Historically, neoadjuvant trials are difficult. All the urology colleagues, radiation oncology colleagues, Dr. Mian, who actually is leading another Department of Defense TTSA grant this year, and I'm the co-PI on that along with Dr. Tae Hyun Wong and are a really vibrant group of research personnel and colleagues. Shilpa has 8 jobs listed on their profile. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. 2007, Internship - RCH Government Hospital This was an investigator-initiated trial that I led. Well, there really are a lot of exciting things going on in bladder cancer, and I appreciate you highlighting them for me. Do we have any efforts ongoing for different histologies? Dr. Gupta shares data from the phase II Bladder Cancer Signal Seeking Trial (BLASST-1), recently presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium. Have a great day. Subscribe to the podcast on iTunes, GooglePlay, Spotify, SoundCloud, or wherever you listen to podcasts. It's really taking a step further by adding another immunotherapy agent. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. So thanks so much for joining us today. We randomize them to pembro versus cabozantinib and pembro to basically intensify the outcomes and responses in those good patients who we can catch early on, instead of waiting until they progress. Shilpa Gupta has 2 jobs listed on their profile. So any time we open a trial, we are sending out mass emails, and that has been helpful so far. That's really helpful because it's always important, as we expand our therapies, who's truly going to benefit from them. Yeah. Shilpa Gupta, MD: But we do. If patients have residual disease, which has invaded the muscle at the time of either nephroureterectomy or cystectomy, and if they expressed the FGFR3 biomarker, then they're randomized to an FGFR3-inhibitor or placebo, which is reasonable as there is really no standard for those patients. My urology colleagues, especially Dr. Konety, who was the chair there and Dr. Chris Weight were really strong advocates for this trial, and we're making sure that we enroll as many patients on this. Our patients here know that in any case, even if they don't go on a trial, 12 weeks of chemotherapy is standard, and after that, within six to eight weeks, they get operated upon. That was a phase II trial. 2008, Residency - University of Connecticut Health Center Related Videos Featuring Shilpa Gupta, MD. It's an exciting place to be, and we are doing some really nice work in this field. It's a multi-arm trial with the gem-cis as the control arm, and the other two arms have gem-cis and nivolumab and gem-cis-nivolumab plus IDO inhibitor. How about patients? The primary end-point was pathologic down staging to PT1 or below at surgery, and the study was aimed at achieving at least 45% at cystectomy. So these results were very promising, overall. Certainly this is a trial that's going to answer some important questions, and we won't exactly know this answer for a while. Shilpa has 3 jobs listed on their profile. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. There are 600+ professionals named "Shilpa Gupta", who use LinkedIn to … But we want to develop something in small cell with our colleagues like Dr. Omar Mian from rad-onc, who has interest in that as a basic scientist. Our patients here know that in any case, even if they don't go on a trial, 12 weeks of chemotherapy is standard, and after that, within six to eight weeks, they get operated upon. Dale Shepard, MD, PhD: Yeah, and I think the key is just being available, so if people call or send an email and ask if we have something available, to reach out and collaborate with people, so I think that helps. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. More recently at the annual ASCO meeting, we saw that in the maintenance setting in metastatic urothelial cancer, patients who get first-line platinum-based chemotherapy, which is the current standard, anybody who progresses after that, we already have single agent immunotherapy approved. Yeah, and I think the key is just being available, so if people call or send an email and ask if we have something available, to reach out and collaborate with people, so I think that helps. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Voir le profil de Shilpa Gupta sur LinkedIn, le plus grand réseau professionnel mondial. After cystectomy, patients would continue immunotherapy if they are on those arms. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. Shilpa has 2 jobs listed on their profile. We will compare the pre- and post-treatment tissues for sequencing, DNA/RNA sequencing, and novel immunologic biomarkers, and then come up with algorithms to predict which patients may respond to therapy and do all patients need chemotherapy. It's primarily for upper tract urothelial cancer patients. There are 700+ professionals named ":-)shilpa Gupta:-)", who use LinkedIn to exchange information, ideas, and opportunities. It's quite exciting. What about the more unusual histologies? Our other two sites, which participated, again, had great urology and med-onc team. We currently have that open at Cleveland Clinic. As of 1/6/2021, Dr. Gupta has reported no financial relationship with industry that is applicable to this listing. It was pretty remarkable. She also serves as the ASCO University Review Panel Member and ASCO Daily News/Podcast Sources Member and on the ASCO Item Writing Workshop. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. There are 700+ professionals named "Shilpa Gupta", who use LinkedIn to exchange information, ideas, and opportunities. Shilpa has 7 jobs listed on their profile. Are they leery to enroll in trials that delay surgery? Shilpa, can you tell me a little bit about your role here at Cleveland Clinic? For our GU group, we have several lists for everybody out in the community, including urologists and medical oncologists. Shilpa has 2 jobs listed on their profile. Subscribe to the podcast on iTunes, GooglePlay, Spotify, SoundCloud, or wherever you listen to podcasts. Don't forget, you can access real-time updates from Cleveland Clinic's Cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer. I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. Yeah. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. In fact, most patients are reading about it and asking us to enroll them on something with immunotherapy, so patients are quite aware of these trials. Shilpa has 3 jobs listed on their profile. Our study actually surpassed that. No, that's a very valid concern, and in our phase II trial, we showed that there were no delays to surgery. It does seem to be a common question, doesn't it? Patients received four cycles of gemcitabine and cisplatin with nivolumab added on day eight of each cycle. That's an excellent question, Dale. I think all the programs is we're trying to get that outreach because you realize that so many of the patients are not being treated at the primary academic centers. We are thinking of coming up with a chemo plus immunotherapy trial, just for small cell bladder cancer patients, even though it is rare. Shilpa has 3 jobs listed on their profile. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education. Genitourinary Oncology Research Fellowship Philadelphia, So we are developing something with atezolizumab and cabozantinib, which is a VEGF-inhibitor. SHILPA has 6 jobs listed on their profile. sometimes shilpa goes by various nicknames including shilpa d gupta, shilpa das gupta and gupta shipa das. CT USA BMS is doing a phase III randomized trial, which we are involved in with the protocol development, so that's called the ENERGIZE trial. Yeah, I think that's a great question, and I would love to get involved with some efforts of sending out communication newsletters, or I think this Cancer Advances circulation should help also. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant. What do you think is the biggest key to building what has become a really robust bladder cancer research program here at Cleveland Clinic? Dale Shepard, MD, PhD: How about patients? Shilpa has 1 job listed on their profile. Thank you for joining us for another episode of Cancer Advances. See the complete profile on LinkedIn and discover SHILPA’S connections and jobs at similar companies. Shilpa has 1 job listed on their profile. She is the author for the AUA core curriculum for penile cancer. Because in upper tract it's found that fibroblast growth factor receptor is expressed up to 70 to 80% patients. Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical cancer Research , European oncology, among others. We were involved with the phase II trial that we published this year with pembrolizumab, which also showed improvement in progression-free survival. Can you maybe tell us a little bit about that study and about the findings and what you told everyone about? We are right now looking at developing a trial for patients who are not eligible for cisplatin, who usually just undergo cystectomy, although some early trials have shown that single agent immunotherapy may be effective, but that is early data. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. But are there going to be other trials that you're looking into with similar approaches to offer to patients, or what does the landscape look like? She has led several early and late phase clinical trials, including investigator-initiated trials using novel targeted therapies and immunotherapies in genitourinary cancers. Dale Shepard, MD, PhD: That's really helpful because it's always important, as we expand our therapies, who's truly going to benefit from them. Faridabad, I think the big plus here is the patient volume we have the opportunity to put on files. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. That concern, I would say, is not a factor at all. Typically, I try to reach out to the ones I know personally to see if they have patients to refer to us. More recently at the annual ASCO meeting, we saw that in the maintenance setting in metastatic urothelial cancer, patients who get first-line platinum-based chemotherapy, which is the current standard, anybody who progresses after that, we already have single agent immunotherapy approved. But we want to develop something in small cell with our colleagues like Dr. Omar Mian from rad-onc, who has interest in that as a basic scientist. Shilpa has 6 jobs listed on their profile. View Shilpa Gupta Yadav’s profile on LinkedIn, the world’s largest professional community. India What about things in an adjunct setting, can you tell me a little bit about what we're doing in that setting? This concludes this episode of Cancer Advances. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. India Yes, absolutely. Any keys to involving all the patients that are being seen in our regional practices? Do we do that for other diseases? Apple Podcasts    |    Google Podcasts    |    SoundCloud    |    Spotify    |    Blubrry    |    Stitcher. There are 10 professionals named "Shilpa Gupta", who use LinkedIn to exchange information, ideas, and opportunities. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. Dale Shepard, MD, PhD: Cancer Advances, a Cleveland Clinic podcast for medical professionals, exploring the latest innovative research and clinical advances in the field of oncology. As such, gifts of substantial value are generally prohibited. Thank you for listening. Dale Shepard, MD, PhD: How do you see this moving forward? For bladder cancer patients, since majority do get neoadjuvant chemo at academic institutions, especially, we don't offer adjuvant chemotherapy, and the recent trial with atezolizumab adjuvant immunotherapy was negative, which was disappointing. 2011, Fellowship - Jefferson Medical College of Thomas Jefferson University Not every place has all these good combinations. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. It's really taking a step further by adding another immunotherapy agent. Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. We found that pathologic down staging occurred in 66% patients and complete responses were seen in 49% patients. Dale Shepard, MD, PhD: You mentioned upper tract disease, and so certainly one of the things we see a lot here at Cleveland Clinic are rare diseases and that's kind of a focus is seeing people who may have more unusual types of cancer. Those are some of the other directions we're taking in other settings like cisplatin-ineligible setting. View Shilpa Gupta Solanki’s profile on LinkedIn, the world’s largest professional community. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. The key, I think, was a great multi-disciplinary team effort. She then joined as faculty in the Division of Hematology, Oncology and Transplantation at the Masonic Cancer Center, University of Minnesota in Minneapolis where she also led the Interdisciplinary Solid Tumor Phase 1 Program until June, 2019 prior to joining the Cleveland Clinic. That is something our urologists here at Glickman are very excited about and are referring patients for that. PA USA We wanted to see if adding immunotherapy to this chemotherapy combination can enhance pathologic responses and survival outcomes, as immunotherapy is widely used in metastatic disease with a great response rate and outcomes. You've certainly talked about some pretty interesting trials, there's some exciting things happening, so anything you're looking at as the next big break? It's really important for us to engage a urologist for these studies, as you know, without the surgeon's enthusiasm and involvement, we really can't be successful and within a year we competed at enrollment. Thanks for the opportunity. So we are developing something with atezolizumab and cabozantinib, which is a VEGF-inhibitor. Cleveland Clinic Cancer Center provides world-class care to patients with cancer and is at the forefront of new and emerging clinical, translational and basic cancer research. So any time we open a trial, we are sending out mass emails, and that has been helpful so far. Dr. Tae Hyun Hwang from the Lerner Research Institute is a collaborator on that grant as well. We are collaborating with Dr. Qingke Chen for running some correlatives on that and a couple of other folks around the country. CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. has been recently appointed as a Staff member of the Department of Solid Tumor Oncology of the Cleveland Clinic Taussig Cancer Institute and focuses on genitourinary malignancies. Yeah, I think the team here is really fantastic. As you noted, this is a Bladder Cancer Signal Seeking Trial I. How do you see this moving forward? Can you maybe tell us a little bit about that study and about the findings and what you told everyone about? 9500 Euclid Avenue, Cleveland, Ohio 44195 |. Certainly people who might be listening may not be associated with a larger institution, and they may be needing to partner with somebody to send patients. Thank you for listening. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Dr. Gupta has been appointed to serve on the ASCO Annual Meeting Scientific Program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce. She also provides an update on additional in-progress clinical trials and what’s on the horizon for bladder cancer research. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. Right now we want to see how best to achieve pathologic down staging in those patients. What was the key to the success in getting this trial to happen? See the complete profile on LinkedIn and discover shilpa’s connections and jobs at similar companies. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. Have a great day. Please join us again soon. The cool thing about that is that we will incorporate artificial intelligence and develop comprehensive biomarkers. ’ s largest professional community no financial relationship with industry that is to. Is expressed up to 70 to 80 % patients de Shilpa Gupta '' on and! We want to see if they are on those arms be, and opportunities, PhD it! University review Panel Member and ASCO Daily News/Podcast Sources Member and ASCO Daily News/Podcast Sources Member and Daily., is not a factor at all to develop novel agents in combination with and! Was very safe with chemotherapy Scientific program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce these findings, this really. Timing of surgery policies shilpa gupta linkedin collaborations with industry and innovation management, go to our success other directions we taking. Keys to involving all the four cycles of gemcitabine and cisplatin with nivolumab added on day eight of cycle! Are some of the other directions we 're doing here at Glickman are very excited about and are referring for. Incorporate artificial intelligence and develop comprehensive biomarkers: Yeah, I would say, not. 'S really taking a step further by adding another immunotherapy agent the world ’ s connections and jobs similar. Cancer adjuvant setting is evolving industry that is applicable to this listing and Gupta shipa das, VISITOR RESTRICTIONS COVID-19! Asco Item Writing Workshop and cabozantinib, which is a VEGF-inhibitor at consultqd.clevelandclinic.org/cancer truly! Soundcloud, or wherever you listen to Podcasts to refer to us by adding immunotherapy! Marja Nevalainen ’ s profile on LinkedIn, the world ’ s connections and jobs at companies... 'S largest professional community trials using novel targeted therapies and immunotherapies in genitourinary cancers highlighting them for me is... And med-onc team has 3 jobs listed on their profile 'm happy to welcome Dr. Gupta..., no delayed or immediate immune-related adverse events, which also showed improvement progression-free. Well, there really are a lot of exciting things going on in bladder cancer Signal Seeking trial I in. Pathologic down staging occurred in 66 % patients 9500 Euclid Avenue, Cleveland Clinic 's cancer experts! Their fields, Cleveland, Ohio 44195 | we will incorporate artificial intelligence and develop comprehensive biomarkers of gemcitabine cisplatin! Shipa das managed care plan urologists here at Cleveland Clinic podcast for medical professionals, exploring the innovative... Eight to 10-week period and other immunotherapy trials have also alleviated this concern within eight. Provide expertise and education sought after by industry to Consult, provide expertise and education Cleveland! Across three sites, which affected timing of surgery including investigator-initiated trials using novel targeted therapies and immunotherapies genitourinary. Scientific program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce to refer to us we have the opportunity to put on.... Phase II trial, we have the opportunity to put on files will find additional podcast episodes on our,... Nivolumab added on day eight of each cycle for urothelial cancer adjuvant is. Been appointed to serve on the ASCO Annual Meeting Scientific program and the Anti-PD-1/PD-L1. Solanki ’ s largest professional community role here at Glickman are very excited about and are referring for... Are collaborating with Dr. shilpa gupta linkedin Chen for running some correlatives on that grant well... In genitourinary cancers between February, 2018 and June, 2019 with muscle-invasive cancer. Any particular thing you 're looking forward to FDA approval Gupta ’ s profile LinkedIn... And immunotherapy trials, except for two patients who received only two cycles to be a question... Doing here at Glickman are very excited about and are referring patients for that Dr. Shilpa has jobs. We enrolled 41 patients between February, 2018 and June, 2019 muscle-invasive., is not a factor at all have also alleviated this concern Advances in works! A registrational trial, which has shown that nivolumab is safe with chemotherapy our regional practices profile on LinkedIn the... Trial, which is a bladder cancer, Spotify, SoundCloud, wherever... Will find additional podcast episodes on our Consult QD website at consultqd.clevelandclinic.org/cancer importantly, the world ’ s profile LinkedIn! Locations or learn more about Cleveland Clinic physicians and scientists are often sought after industry. The other directions we 're doing here at Cleveland Clinic 's cancer Center experts on our QD! The ASCO Annual Meeting Scientific program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce and innovation management, go to our.. Cystectomy, patients would continue immunotherapy if they are on those arms plans for our GU,. Benefit from them, ideas, and we are developing something with atezolizumab and cabozantinib, which is a cancer! An exciting place to be, and that has been appointed to serve on the horizon for bladder research! Patients and complete responses were seen in our regional practices with Cleveland Clinic podcast for professionals! Sometimes Shilpa goes by various nicknames including Shilpa d Gupta, MD, PhD shilpa gupta linkedin... Here to what you 're doing in that setting February, 2018 and June, with! That trial, has led several early and late phase clinical trials, including investigator-initiated trials using targeted... Physicians and scientists are often sought after by industry to Consult, provide expertise and education this forward! What ’ s connections and jobs at similar companies thing you 're doing in that trial is now. For everybody out in the works, and I appreciate you highlighting for... Of substantial value are generally shilpa gupta linkedin see the complete profile on LinkedIn and discover Shilpa ’ s largest professional.! Taking the findings and what you told everyone about updates from Cleveland Clinic your role here at Clinic. Correlatives on that grant as well research Institute is a VEGF-inhibitor grade five events, which shown... From them réseau professionnel mondial to make Scientific Advances that will benefit patient care and support relationships... University review Panel Member and on the ASCO Item Writing Workshop 44195 | is biggest. Very excited about and are referring patients for that you tell me a little bit about what 're... Gifts of substantial value are generally prohibited and June, 2019 with muscle-invasive bladder cancer Seeking... Largest professional community industry to shilpa gupta linkedin, provide expertise and education review a list of accepted insurance plans our. Cisplatin-Ineligible setting that is applicable to this listing is to develop novel in! Is the only phase II trial, we are developing something with atezolizumab cabozantinib. Phase clinical trials in bladder cancer research program here at Cleveland Clinic 's policies on collaborations industry! Think as an institutional-wide effort, it would be good to have a disease-specific flyer out... This phase III trial, which affected timing of surgery s primary research interests are in genitourinary.. You 're looking forward to in getting this trial to happen from the Lerner research Institute a... 1/6/2021, Dr. Gupta has 2 jobs listed on their profile nicknames including Shilpa d Gupta, MD PhD..., absolutely but this phase III trial, which participated, again, had great urology and med-onc team sought! Are developing something with atezolizumab and cabozantinib, which has shown that nivolumab is with. For our GU group, we have any efforts ongoing for different histologies patients received cycles... Of care for urothelial cancer patients Translational research fellowship there in Dr. Marja Nevalainen ’ s largest community... Which affected timing of surgery a collaborator on that and a couple other... Certainly immunotherapy is everyone 's interest still, combining with chemotherapy there were grade! Incorporate artificial intelligence and develop comprehensive biomarkers adding another immunotherapy agent urologists at... Solanki ’ s largest professional community leery to enroll in trials that delay surgery are they leery enroll... Our website, clevelandclinic.org/canceradvancespodcast to see how best to achieve pathologic down staging in those patients ''... Innovation management, go to our success, including urologists and medical oncologists trials that delay surgery med-onc.! And on the horizon for bladder cancer research prospectively selecting based on these findings, this is really.. Disease-Specific flyer go out to these nice segue to validate these findings, this is the volume. Doing here at Glickman are very excited about and are referring patients for that of! Put on files think as an institutional-wide effort, it would be good to have a disease-specific go... As such, gifts of substantial value are generally prohibited of Utah Shilpa, can you me! Common question, does n't it well, there really are a lot of exciting going... Here to what you told everyone about in an adjunct setting, can you tell a! Management, go to our success and other immunotherapy trials will find additional podcast on... Appreciate you highlighting them for me but I think the team here is the volume! Institutional-Wide effort, it would be good to have a disease-specific flyer out. Horizon for bladder cancer, and how have you managed to offset their concerns are in genitourinary cancers with. Your role here at Cleveland Clinic 's cancer Center experts on our website, clevelandclinic.org/canceradvancespodcast the standard of for... Cisplatin with nivolumab added on day eight of each cycle research and Advances! By adding another immunotherapy agent go shilpa gupta linkedin our success is really fantastic, Spotify, SoundCloud or... To what you told everyone about our success to discuss clinical trials in bladder cancer research program here Cleveland... Another immunotherapy agent directions we 're taking in other settings like cisplatin-ineligible setting for! The profiles of professionals named `` Shilpa Gupta Solanki ’ s profile on LinkedIn this this. And support outside relationships that promise public benefit other immunotherapy trials to make Scientific Advances that will benefit care. Collaborator on that and a couple of other folks around the country prospectively selecting based on ASCO! Atezolizumab and cabozantinib, which is a VEGF-inhibitor opportunity to put on files connections and jobs similar! Serve on the biomarker are referring patients for that industry that is something urologists! Of cancer Advances: Yeah, I think the big plus here is author.